UK HRT Prescription Charges: What NHS Price Changes Mean for Menopausal Women

UK HRT prescription charges have not risen for 2026/27. The standard NHS prescription charge in England is frozen at £9.90 per item for a second consecutive year, and the dedicated Hormone Replacement Therapy Prescription Prepayment Certificate (HRT PPC) remains £19.80 a year. Yet a price freeze is not the same as affordable access: menopause charities report that 1 in 10 women say they have stopped taking HRT because of cost, even as more than 800,000 women in England now hold an HRT prepayment certificate, according to NHS England. This article sets out exactly what has changed with NHS HRT prescription costs in 2026, why the freeze does not resolve the deeper access problem, and what menopausal women can do now to reduce their costs.

What Has Changed With NHS Prescription Charges in 2026

For 2026/27, the Department of Health and Social Care has frozen the NHS prescription charge in England at £9.90 per item, the second year running it has not increased. Prepayment certificate prices are frozen too: the 12-month PPC stays at £114.50, the three-month PPC at £32.05, and the HRT-specific certificate at £19.80.

The HRT PPC, introduced in April 2023, lets women pay a single annual sum instead of £9.90 per item every time a prescription is dispensed. Because most women on combined HRT regimens (an oestrogen product plus a progestogen, and sometimes testosterone) need multiple items every month, the certificate typically pays for itself after just two prescription charges and can save a regular user more than £200 a year compared with paying item by item, according to NHS guidance. NHS England data cited in August 2026 shows the scheme has grown substantially, from around 500,000 certificate holders in its first year to over 800,000 now.

Crucially, the HRT PPC does not cover every hormone therapy product. Some formulations, including certain testosterone preparations prescribed off-label for menopausal women, fall outside the certificate and must still be paid for as separate items, or are not routinely available on NHS prescription at all. That gap matters because testosterone is increasingly used alongside oestrogen for symptoms such as low libido and persistent fatigue.

Why HRT Costs Still Matter for Menopausal Women

A frozen charge protects women from a price rise, but it does not remove the charge itself, and most women going through perimenopause and menopause, typically between their mid-40s and mid-50s, are below the age exemption threshold of 60 and do not qualify for free prescriptions on age grounds alone. Around 89% of all NHS prescriptions in England are already dispensed free under various exemptions, but working-age women without another qualifying condition are largely excluded from that group.

The social impact falls hardest on lower-income households. For a woman without a prepayment certificate who needs two or three HRT items a month, the annual cost can exceed £200, a sum that competes directly with household bills at a time when many families are still managing tight budgets. Charities say this is precisely why the reported figure of 1 in 10 women stopping HRT due to cost is concerning: stopping treatment abruptly can bring back disruptive symptoms, including sleep loss, anxiety and reduced ability to work, which in turn can affect earnings and job retention.

There is also a documented inequality dimension. A population-based cohort study published in BMJ Medicine, led by Dr Jennifer Hirst at the University of Oxford's Nuffield Department of Primary Care Health Sciences, examined records for almost two million women aged 40 to 60 in English primary care and found that only around 19% received two or more HRT prescriptions over the study period. Prescribing rates were consistently lower among women from minority ethnic groups and those living in more deprived areas, and women in these groups were more likely to receive only a single prescription and not continue treatment. "These findings show that the women who may need HRT most, those with higher cardiovascular risk, are often the least likely to receive appropriate treatment," Dr Hirst said. The prescription charge structure sits on top of these existing inequalities rather than resolving them.

GP and Charity Reaction

Menopause care has become a significant part of primary care workload as public awareness of symptoms and treatment options has grown since public health campaigns of recent years. GPs continue to report high demand for menopause consultations, and short appointment slots make it harder to discuss the full range of HRT options, including body-identical formulations, within a single visit.

Menopause charities argue that the prescription charge freeze, while welcome, does not go far enough. Their position is that HRT should be treated as a long-term, ongoing treatment similar to other conditions that already carry exemptions, rather than being charged per item in the same way as short-course medicines. The 1 in 10 figure on women discontinuing treatment because of cost is being used by campaigners to press the government to consider further changes, including wider awareness of the HRT PPC itself, since take-up, while growing, still leaves many eligible women paying more than they need to simply because they are unaware the certificate exists.

The arrival of Yvette Cooper as Health and Social Care Secretary in July 2026 has brought fresh scrutiny to NHS charging and access more broadly, alongside her stated commitment to reform maternity services following recent scandals. Whether that wider reform agenda extends to a formal review of prescription charging for long-term conditions such as menopause remains to be confirmed, but campaigners are pushing for HRT affordability to be part of the conversation as the government's 10-Year Health Plan is implemented.

How to Manage HRT Prescription Costs

Women in England paying for HRT item by item should check whether an HRT PPC would save them money: it almost always will if more than two items are needed within a year. Practical steps include:

Apply for an HRT PPC via the NHS Business Services Authority (nhsbsa.nhs.uk) or through gov.uk if three or more HRT items are likely to be needed in 12 months.
Check exemption eligibility first: some women qualify for free prescriptions on medical or income grounds (for example, via a medical exemption certificate for a qualifying condition, or through NHS Low Income Scheme support) and would not need a PPC at all.
Ask the GP practice or pharmacist to confirm which specific HRT products are covered by the PPC before assuming all prescribed items are included, since some testosterone preparations and specialist formulations are not.
Consider a standard PPC instead of the HRT-specific one if other regular prescriptions are also needed, since the annual standard certificate at £114.50 may work out cheaper overall for some households.
Contact NHS 111 or a GP promptly if symptoms return after stopping HRT for cost reasons, rather than remaining untreated, since a review of exemption options or generic alternatives may reduce the ongoing cost.

Readers can also compare wider household budgeting approaches in Baba International's finance coverage, which regularly tracks NHS-related charges alongside broader UK cost-of-living changes.

What This Means Going Forward

The freeze on NHS prescription charges for 2026/27 is a modest, protective measure rather than a structural fix. It prevents costs from rising, but it leaves in place a system where working-age menopausal women pay per item unless they proactively apply for a prepayment certificate, and where access already varies by ethnicity, deprivation and region according to the Oxford-led BMJ Medicine research. The gap between the more than 800,000 women who have taken up the HRT PPC and the far larger population of women prescribed HRT in England suggests significant unclaimed savings remain on the table simply through low awareness of the certificate.

With a new Health Secretary in post and a 10-Year Health Plan being rolled out, campaigners will be watching for any commitment to bring HRT prescribing costs and access more explicitly into the government's women's health agenda, rather than treating this year's freeze as the final word. For more UK-focused health policy analysis, see Baba International's health articles and the wider coverage available at Baba International.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

Has the NHS prescription charge for HRT gone up in 2026?

No. The standard NHS prescription charge in England, which applies to individual HRT items, is frozen at £9.90 for 2026/27, the second year in a row it has not increased. The HRT Prepayment Certificate is also unchanged at £19.80 a year.

What is the HRT Prepayment Certificate and how much does it cost?

The HRT PPC is a certificate that covers an unlimited number of specified HRT medicines for 12 months for a single payment of £19.80. It is designed for women who need three or more HRT prescription items a year, since it typically pays for itself after two standard prescription charges.

Does the HRT PPC cover all hormone replacement therapy products?

No. Some products, including certain testosterone preparations sometimes prescribed for menopausal symptoms, are not covered by the HRT PPC and must be paid for separately or may not be routinely available on NHS prescription.

Why are some women still stopping HRT because of cost?

Charity data indicates around 1 in 10 women report stopping HRT due to cost, often because they are unaware of the HRT PPC, do not qualify for an exemption, or are managing several prescriptions where the combined cost is difficult to absorb, particularly in lower-income households.